Posts Tagged ‘MSHL’

Marshall Edwards, Inc. (MSHL) grows from publication of new study

Wednesday, July 27th, 2011

Marshall Edwards, Inc.(Nasdaq: MSHL) shares leaped 172.7% to $3.19, after it announced the publication of results from a pre-clinical study of NV-128 showing activity in chemotherapy-resistant ovarian cancer stem cells. Volume for the stock topped 2.5 million shares, dwarfing a daily average around 75,000.

The San Diego-based Marshall Edwards, an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced in news release dated July 27 the publication of results from a pre-clinical study of NV-128 showing activity in chemotherapy-resistant ovarian cancer stem cells. NV-128 is the prodrug of the Company’s investigational compound and lead mitochondrial inhibitor drug candidate, NV-344.

The publication, entitled “Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells,” is available on the Molecular Cancer Therapeutics website and scheduled to print in the August issue of the journal.

Previous studies conducted at Yale University showed that NV-128 is able to inhibit tumor growth in an ovarian cancer animal model without inducing significant toxicity, suggesting a sufficient therapeutic window that may allow compounds of this class to be safely administered to patients. Marshall Edwards plans to complete the required pre-clinical studies of NV-344 to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the first quarter of 2012.

In the same release, company CEO Daniel Gold said, “This study exemplifies the importance of our ongoing collaboration with … Yale University as well as our continuing commitment to enhancing our pipeline of novel drug candidates.

“We are excited about the progress we are making with both of our lead candidates, NV-143 and NV-344, and look forward to reporting on their clinical development in the months ahead.” Gold concluded.

Marshall Edwards, Inc. is focused on the clinical development of novel anti-cancer therapeutics. The Company’s lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism.

PFSW soars, MU far from mute, MSHL moody

Wednesday, March 23rd, 2011

PFSWEb Inc. (Nasdaq: PFSW) stepped on the accelerator Wednesday, gaining 25.4% in price to $4.15. Volume for the stock was nearly 630,000 shares, trouncing its daily average of 86,789, on better-than-expected Q4 earnings.

Micron Technology Inc. (Nasdaq: MU) proved among the busiest stocks on Wall St. Wednesday, trading in 39.5 million shares, just shy of its daily average around 41 million. Share prices budged 2.7% higher to $10.62, as investors awaited the release of MU’s Q2 financials results.

Marshall Edwards Inc. (Nasdaq: MSHL) slumped 15.7% Wednesday to register at $1.56 near the close. Volume for the stock was 143,091, or nearly double its usual volume.

MSHL moves, MSFT busy, MAJC miserable

Monday, March 21st, 2011

Marshall Edwards, Inc.(Nasdaq : MSHL) shares boosted 13.3% to $1.70, on volume of 45,250 shares, shy of its all-day average of 57,758, after it announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

Microsoft Corporation (Nasdaq: MSFT) dealt in 26.2 million shares, making it one of the leaders, but still short of its average of 58.7 million. Shares for the computer behemoth advanced 2.1% to $25.33, amid strength in the tech industry.

Majestic Capital Inc. (Nasdaq: MAJC) lost its parachute and dropped 72.7% in price Monday to $1.18, on volume of 1.3 million shares, towering over a daily average of around 5,300, as the company mulls bankruptcy following a termination of a merger agreement with Bayside Capital Partners.

MSHL marches, CSCO deals, GTIMD down

Wednesday, January 26th, 2011

Marshsall Edwards Inc. (Nasdaq: MSHL) shares spiked 21.8 percent to $2.63, on volume of 114,403 shares, tripling its daily average.

Cisco Systems Inc. (Nasdaq: CSCO) was among the volume leaders Wednesday, trading in 46.2 million shares compared to a daily average of 72.8 million. Share prices shaved off 0.6 percent to $21.41.

Good Times Restaurants Inc. (Nasdaq: GTIMD) shares jettisoned 34.3 percent to $3.11 Wednesday, on volume of 186,771 shares, compared to a daily average of 5,000. The Colorado-based restaurant chain said December was its fifth consecutive month of same-store sales increases. It said that same-store sales were up 13.4 percent in the just-completed first quarter of fiscal 2011 from a year earlier.

Buzz Stock of the Day – Novogen (NVGN)

Wednesday, July 8th, 2009

Warning: fopen(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home3/taylor/public_html/buzzstocks.com/wp-content/plugins/brad-stock-quote/stock-quote.php on line 38

Warning: fopen(http://download.finance.yahoo.com/d/quotes.csv?s=NVGN&f=sl1d1t1c1ohgvbacwj3n): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home3/taylor/public_html/buzzstocks.com/wp-content/plugins/brad-stock-quote/stock-quote.php on line 38

Warning: fgetcsv() expects parameter 1 to be resource, boolean given in /home3/taylor/public_html/buzzstocks.com/wp-content/plugins/brad-stock-quote/stock-quote.php on line 39

Warning: fclose() expects parameter 1 to be resource, boolean given in /home3/taylor/public_html/buzzstocks.com/wp-content/plugins/brad-stock-quote/stock-quote.php on line 40

Shares of Australian pharmaceutical company Novogen Ltd. (Nasdaq: NVGN) continued their climb today after closing up 24 percent on the day yesterday.

Shares were up as much as 83 percent presumably another run on yesterday’s news that researchers found that the investigational anti-tumor drug, phenoxodiol, to be effective in killing cancer cells.
[–quote–]
Phenoxodiol is licensed by Marshall Edwards (Nasdaq: MSHL), which is majority owned by Novogen Ltd.

The results make phenoxodiol a promising candidate for the treatment of pathologically activated lymphocytes such as those in acute lymphoid leukemia, or diseases driven by T-cell proliferation such as autoimmune diseases and graft-versus-host disease, according to an article published in the Haematologica Journal on June 16.